Abstracts tagged "cytokines"

Abstract Number: 0025 • ACR Convergence 2024
Vagus Nerve Stimulation: A Promising Approach to Alleviate Pain and Systemic Inflammation in Slow and Rapid Models of Osteoarthritis
Shivmurat Yadav¹, Timothy Griffin², Matlock Jeffries², Stavros Stavrakis³ and Mary Beth Humphrey⁴, ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³University of Oklahoma, College of Mediicine, Oklahoma City, OK, ⁴University of Oklahoma College of Medicine, Oklahoma City, OK
Background/Purpose: Osteoarthritis (OA) causes joint pain, stiffness, swelling, and functional impairment. Pain signals reach the brain, influencing inflammatory and immune responses through the parasympathetic efferent…
Abstract Number: 0878 • ACR Convergence 2024
YY1 a Potential Modulator of IL17/IL23 Axis in Psoriasis Disease
vinod kumar, Tammana Sharma, Rahul Mahajan, Tarun Narang, Sunil Dogra and Sanjeev handa, PGIMER, Chandigarh, Chandigarh, India
Background/Purpose: Psoriasis is an inflammatory skin disease that progresses and worsens if left unattended. IL17 plays a pivotal role as a pathogenic trigger. Despite Th17…
Abstract Number: 1599 • ACR Convergence 2024
Glucocorticoids versus Glucocorticoids Plus Cyclophosphamide in Eosinophilic Granulomatosis with Polyangiitis with Poor-Prognosis Factors: A Target Trial Emulation Study
Boris Sorin¹, Matthias Papo¹, Renato Alberto Sinico², Vítor Silvestre Teixeira³, Nils Venhoff⁴, Maria-Letizia Urban⁵, Michele Iudici⁶, Juliane Mahrhold⁷, Francesco Locatelli⁸, Giulia Cassone⁹, Franco Schiavon¹⁰, Benjamin Seeliger¹¹, Thomas Neumann¹², Claudia Feder¹³, Claus Kroegel¹⁴, Matthieu Groh¹⁵, Chiara Marvisi¹⁶, Maxime Samson¹⁷, Thomas Barba¹⁸, David Jayne¹⁹, Arianna Troilo²⁰, Jens Thiel²⁰, Bernhard Hellmich²¹, Sara Monti²², Carlomaurizio Montecucco²³, Carlo Salvarani²⁴, Jean-Emmanuel Kahn²⁵, Bernard Bonnotte²⁶, Cécile-Audrey Durel²⁷, Xavier Puéchal²⁸, Luc Mouthon²⁹, Loïc Guillevin³⁰, Giacomo Emmi³¹, Augusto Vaglio³², Raphael Porcher³³ and Benjamin Terrier³⁴, and the French Vasculitis Study Group (FVSG) and the European EGPA Study Group (EESG), ¹Department of Internal Medicine, Cochin Hospital, National Referral Center for Rare Systemic Autoimmune and Autoinflammatory Diseases of Ile de France, East and West, Paris Cité University, Assistance Publique – Hôpitaux de Paris, Paris, France, ²Nephrology and Dialysis Unit, IRCCS Humanitas Research Hospital, Milan, Italy, ³Department of Rheumatology, Faro Hospital, Algarve, Portugal, ⁴Medical Center - University of Freiburg, Internal Medicine, Department of Rheumatology and Clinical Immunology, Freiburg, Germany, ⁵Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁶Department of Internal Medicine, Cochin Hospital, National Referral Center for Rare Systemic Autoimmune and Autoinflammatory Diseases of Ile de France, East and West, Paris Cité University, Assistance Publique – Hôpitaux de Paris and Division of rheumatology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland, Paris, France, ⁷Department of Internal Medicine, Rheumatology, Pulmonology, Nephrology and Diabtologyy and Immunology, ERN-RITA Reference Center, Vasculitis-Center Tübingen-Kirchheim, Medius Kliniken Kirchheim, University of Tübingen, Kirchheim-Teck, Germany, ⁸Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, ⁹Clinical and Experimental Medicine PhD Program, Azienda USL-IRCCS di Reggio Emilia and Universita di Modena and Reggio Emilia, Modena, Italy, ¹⁰Department of Medicine DIMED, Division of Rheumatology, University of Padua, Padua, Italy, ¹¹Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany, ¹²Department of Rheumatology, Clinic of Internal Medicine III, Jena University Hospital, Jena, Germany and Division of Rheumatology, Immunology and Rehabilitation, Kantonsspital St Gallen, St Gallen, Switzerland, Jena, Germany, ¹³Department of Rheumatology, Clinic of Internal Medicine III, Jena University Hospital, Jena, Germany, ¹⁴Department of Pneumology and Allergology, Clinic of Internal Medicine I, Jena University Hospital, Jena, Germany, ¹⁵Foch, Suresnes, France, ¹⁶Rheumatology Unit Universita di Modena and Reggio Emilia, Modena, Italy, ¹⁷Department of Internal Medicine and Clinical Immunology, François-Mitterrand Teaching Hospital, University of Bourgogne-Franche-Comté, Dijon, France, ¹⁸Department of Internal Medicine, Hôpital Edouard Herriot, Lyon, France, ¹⁹University of Cambridge, Cambridge, United Kingdom, ²⁰Department of Rheumatology and Clinical Immunology, Medical Center – University of Freiburg, Faculty of Medicine, Freiburg, Germany, ²¹Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ²²IRCCS Istituto Auxologico Italiano, Milan, Italy, ²³IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, ²⁴Azienda USL-IRCCS di Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia, Italy, Reggio Emilia, Italy, ²⁵Department of Internal Medicine, Ambroise Paré Hospital, Assistance Publique - Hôpitaux de Paris, Université de Versailles Saint-Quentin-en-Yvelines, Boulogne-Billancourt, France, Boulogne Billancourt, France, ²⁶Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France., Dijon, France, ²⁷Edouard Herriot University Hospital, Lyon, France, ²⁸National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ²⁹Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l'Est et de l'Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ³⁰National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, ³¹Department of Medical, Surgery and Health Sciences, University of Trieste, and Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste, Italy, ³²Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Firenze, Florence, Italy, ³³Department of Rheumatology, Bicêtre AP-HP Hôpital, Université Paris-Saclay, Paris, Ile-de-France, France, ³⁴Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel necrotizing vasculitis characterized by asthma, blood and tissue eosinophilia and vasculitis affecting multiple organs. According to…
Abstract Number: 2397 • ACR Convergence 2024
Increase of IL10 and IFNa2 Are Associated to Clinical Activity in Systemic Lupus Erythematous Patients
Elena Grau García¹, Marta De la Rubia Navarro², Samuel Leal Rodriguez¹, José Ivorra-Cortés³, Carmen Riesco Barcena⁴, Anderson Huaylla Quispe⁴, Laura Mas Sánchez⁵, Pablo Muñoz Martínez⁶, Daniel Ramos Castro⁴, Alba Torrat noves⁷, Iago Alcantara Alvarez², Belén Villanueva Mañés², Miguel Simeo Vinaixa², Andrés Pérez Hurtado⁴ and Jose A Román-Ivorra⁸, ¹HUP La Fe, Valencia, Spain, ²Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ³Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, ⁴Rheumatology Department. HUP La Fe, Valencia, Spain, ⁵Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, ⁶Hospital Universitario y Politècnico La Fe, Sagunto, Spain, ⁷Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, ⁸Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain
Background/Purpose: Systemic lupus erythematous (SLE) is an autoimmune disease characterized by deregulation of cytokine production. Interferon (IFN) is a proinflamatory cytokine considered as a key…
Abstract Number: 0041 • ACR Convergence 2024
Disease Activity and Serological Inflammatory Markers Are Associated with TNF-a and IL-6-Induced Osteoclasts, but Not with RANKL-Induced Osteoclasts in Peripheral Blood Monocytes from Patients with Rheumatoid Arthritis
Yokota Kazuhiro¹, Yoshimi Aizaki¹, Miyoko Sekikawa², Hiroshi Kajiyama¹, Yasuto Araki¹, Yuho Kadono², Yuji Akiyama¹ and Toshihide Mimura¹, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, Iruma-gun, Saitama, Japan, ²Department of Orthopaedic Surgery, Saitama Medical University, Saitama, Japan, Iruma-gun, Saitama, Japan
Background/Purpose: We previously reported that a combination of TNF-α and IL-6 induces mouse osteoclast (OC)-like cells and human OCs with bone resorption activity [Arthritis &…
Abstract Number: 0879 • ACR Convergence 2024
A Novel, Oral, Allosteric Inhibitor of Tyrosine Kinase 2 (TYK2) Demonstrates In Vitro Potency, Selectivity, and In Vivo Efficacy in Mouse Models of Psoriasis
Razika Hussein¹, Pamela Tsuruda¹, Shahab Mortezaei¹, Nicky Ferdyan¹, Christopher Wegerski², Karthik Srinivasan¹, Gavin Hirst¹ and Neelufar Mozaffarian¹, ¹Atomwise Inc., San Francisco, ²Atomwise Inc., San Francisco, CA
Background/Purpose: Tyrosine kinase 2 (TYK2), a member of the Janus kinase (JAK) family, plays a key role in several inflammatory diseases. Orthosteric, small molecule inhibitors…
Abstract Number: 1622 • ACR Convergence 2024
18F-FDG PET/CT in LVV During Active and Inactive Disease Phases Is Associated with the Metabolic Profile, but Not with Macrophage-related Cytokines: Results of an Integrated Analysis
Dimitrios Anastasios Palamidas¹, Georgios Kalykakis², Dimitra Benaki³, Loukas chatzis¹, Ourania Argyropoulou⁴, Panagiota Palla⁴, Antonia Kollia⁵, Pavlos Kafouris⁵, Marinos Metaxas⁵, Andreas Goules⁶, Emmanuel Mikros⁷, Konstantinos Kambas⁸, Constantinos Anagnostopoulos⁵ and Athanasios Tzioufas⁹, ¹Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Cholargos Athens, Greece, ²Department of Informatics, Ionian University, Kerkyra, Greece, Athens, Greece, ³Department of Pharmaceutical Chemistry, School of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁴Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Athens, Greece, ⁵PET-CT Department & Preclinical Imaging Unit, Center for Experimental Surgery, Clinical & Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece., Athens, Greece, ⁶GENERAL HOSPITAL LAIKO ATHENS, Athens, Greece, ⁷Department of Pharmaceutical Chemistry, School of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece., Athens, Greece, ⁸Laboratory of Molecular Genetics, Department of Immunology, Hellenic Pasteur Institute, Athens, Greece., Athens, Greece, ⁹LAIKO HOSPITAL, Athens, Greece
Background/Purpose: Giant cell arteritis (GCA) may affect temporal arteries (cranial-GCA) or may present as a systemic disease extended to the large vessels [Large Vessel Vasculitis…
Abstract Number: 2432 • ACR Convergence 2024
In Vitro and In Vivo Evidence of the Steroid-Sparing Potential of Afimetoran, an Equipotent Toll-Like Receptor 7/8 Dual Antagonist
Shailesh Dudhgaonkar¹, Siva Subramani², Puneet Chopra², Anjuman Rudra², Sourabha Palachandra², Nikita Sanjay Bhatt², Veeresh Pabbala², Sabariya Selvam², Mobeen Shaik², Amit Anand², Benjamin King³, Kristina Chadwick³, Alaric Dyckman³, Qihong Zhao³, Frédéric Baribaud³, Ramya Janardhana⁴ and Vineeta Shobha⁵, ¹Bristol Myers Squibb, Bangalore, India, ²Biocon BMS Research Center, Syngene International Ltd, Bangalore, India, ³Bristol Myers Squibb, Princeton, NJ, ⁴St. John’s Medical College, Bengaluru , India, Bangalore, India, ⁵St. John’s Hospital, Bangalore, India
Background/Purpose: SLE is a highly heterogeneous chronic autoimmune disease, with glucocorticoid therapy as the standard of care. SLE control requires high steroid doses; long-term use…
Abstract Number: 0043 • ACR Convergence 2024
Inflammatory and Angiogenic Serum Profile of Refractory Rheumatoid Arthritis
Manon Lesturgie-Talarek¹, Virginie Gonzalez², ALICE COMBIER³, Marion THOMAS⁴, Margaux Boisson⁵, Sandrine Carves³, Sarah Wanono³, Lucie Poiroux³, Anne Cauvet¹, Sophie Hecquet⁶, Yannick Allanore⁷ and Jérôme Avouac⁸, ¹Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, France, ²Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, Ile-de-France, France, ³Hôpital Cochin - Université Paris Cité, Paris, France, ⁴APHP, Paris, France, ⁵Hôpital Cochin - Université Paris Cité, Paris, ⁶Cochin Hospital, Paris, France, ⁷Université Paris Cité, Paris, France, ⁸Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Despite the emergence of new therapies, a considerable proportion of individuals with rheumatoid arthritis (RA) still endure symptoms, giving rise to the concept of…
Abstract Number: 0881 • ACR Convergence 2024
Cytokine Profile of Newly Diagnosed Patients with Isolated Polymyalgia Rheumatica
Patricia Harkins¹, Sharon Cowley², Robert Harrington³, David Kane⁴, Jean Dunne⁵, Niall conlon⁶ and Richard Conway⁷, ¹Trinity College Dublin, Dublin 8, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, ³St. James's Hospital, Dublin, Dublin, Ireland, ⁴Tallaght University Hospital & Trinity College Dublin, D24, Ireland, ⁵Trinity College Dublin, Dublin, ⁶Trinity Colleg Dublin, Dublin, ⁷Trinity College Dublin, Dublin, Ireland
Background/Purpose: Despite polymyalgia rheumatica (PMR) being the most common inflammatory rheumatic disease in those over the age of 50 years, there remains a significant unmet…
Abstract Number: 1650 • ACR Convergence 2024
IL-33 Expands Plasma Cells, Disrupts Germinal Centers and Increases Autoantibody Production
Andre Limnander¹, Eva Conde¹, Seblewongel Asrat², Andrea Vecchione², Kaitlyn Gayvert², Paulina Pedraza², Carley Tasker², Sharon Huang², Dmitry Yarilin², Dylan Birchard², Li-Hong Ben², Wei Keat Lim², Andrew Murphy², Matthew Sleeman² and Jamie orengo¹, ¹Regeneron Pharmaceuticals, Tarrytown, NY, ²Regeneron Pharmaceuticals, Tarrytown
Background/Purpose: IL-33 is a pro-inflammatory cytokine that plays a role in asthma, COPD and autoimmune diseases. The role of IL-33 on B cell maturation and…
Abstract Number: 2595 • ACR Convergence 2024
TGF-β Activated Kinase 1 (TAK1) Inhibition Suppresses Synovial Inflammation and Tissue Destruction Mediated by Activated Juvenile Idiopathic Arthritis Synovial Fibroblasts
Meena Afroze Shanta¹, Paul Panipinto², Anil Singh³, Peter Nigrovic⁴, Lauren Henderson⁵ and Salahuddin Ahmed³, ¹College of Pharmacy and Pharmaceutical Science, Washington State University, Spokane, WA, ²Washington State University College of Pharmaceutical Science and Molecular Medicine, Spokane, WA, ³Washington State university, Spokane, WA, ⁴Boston Children's Hospital, Brookline, MA, ⁵Boston Children's Hospital, Watertown, MA
Background/Purpose: Synovial inflammation is a common manifestation of juvenile idiopathic arthritis (JIA), often accompanied by debilitating synovial hyperplasia. The current study aims to characterize the…
Abstract Number: 0071 • ACR Convergence 2024
Stage-Specific Roles of Interleukin-23/Interleukin-17 Axis and Type 1 Regulatory T Cells Dynamics in Axial Spondyloarthritis
Jina Yeo¹, Min-Gang Kim², Hee Sung Kwon³, Mi Ryoung Seo¹, Hyo-Jin Choi¹, YunJae Jung⁴, Eun Young Lee⁵ and Han Joo Baek⁶, ¹Division of Rheumatology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea, ²Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, ⁴Department of Microbiology, College of Medicine, Gachon University, Incheon, Republic of Korea, ⁵3Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Inchon, South Africa
Background/Purpose: The interleukin (IL)-23/IL-17 pathway is central to axial spondyloarthritis (axSpA) pathogenesis, yet treatments targeting IL-23 show inconsistent effectiveness across spondyloarthritis subtypes. We hypothesized that…
Abstract Number: 0882 • ACR Convergence 2024
Brepocitinib, a Selective TYK2/JAK1 Inhibitor Under Evaluation for the Treatment of Dermatomyositis, Reduces Inflammatory Cytokine Signaling and Interferon-induced Apoptosis in Primary Human Epidermal Keratinocytes
Jiří Vencovský¹, Alexandra Goriounova², Lisa McConnachie² and Brendan Johnson², ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Priovant Therapeutics, Durham, NC
Background/Purpose: Dermatomyositis (DM) is characterized by inflammatory and degenerative changes of skin and muscle and upregulation of Type I IFN-regulated gene and protein levels in…
Abstract Number: 1662 • ACR Convergence 2024
Using Circulating Soluble Serum Mediator Profiles to Understand the Mechanisms Driving Disease Flare and Drug-free Remission in Rheumatoid Arthritis
Amy Anderson¹, Fiona Rayner², Abbie Degnan¹, Imogen Wilson¹, Julie Diboll¹, Jasmine Sim¹, Andrew Melville³, Stefan Siebert³, Iain McInnes⁴, Carl Goodyear³, Catharien Hilkens¹, Andrew Filer⁵, Karim Raza⁵, Christopher Buckley⁶, Kenneth Baker¹, Arthur Pratt² and John Isaacs¹, ¹Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ²Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, ³School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁴University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ⁵Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, ⁶Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom
Background/Purpose: Little is known of the factors that trigger disease relapses/flares in patients with rheumatoid arthritis (RA). The underpinning mechanisms have been difficult to study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].